Tue Sep 10 17:09:00 UTC 2024: ## Altimmune Corrects Data on Pemvidutide’s Body Composition Effects

**GAITHERSBURG, MD – September 10, 2024** – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has corrected data presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) regarding the body composition changes observed in a Phase 2 sub-study of its investigational obesity drug, pemvidutide.

The company’s initial release reported a 25.6% reduction in visceral adipose tissue (VAT) and a 20.1% reduction in subcutaneous adipose tissue at Week 48. The corrected data shows a 28.3% reduction in VAT and a 19.5% reduction in subcutaneous adipose tissue.

These corrections do not impact the overall positive findings of the study, which showed that pemvidutide led to a significant reduction in VAT, a key risk factor for cardiovascular disease, while also demonstrating class-leading preservation of lean mass.

The study, which included 67 subjects from the Phase 2 MOMENTUM obesity trial, showed that pemvidutide significantly preserved lean mass compared to total mass loss, with a lean loss ratio of only 21.9%. Notably, lean mass preservation was even greater in individuals over 60 years of age, who are at higher risk for frailty and fractures.

“Preservation of lean mass is crucial for overall health, especially in older individuals,” said Dr. Scott Harris, Altimmune’s Chief Medical Officer. “The data underscores pemvidutide’s potential to offer a significant benefit to individuals struggling with obesity, particularly in terms of maintaining muscle mass and reducing cardiovascular risk.”

Pemvidutide is a novel GLP-1/glucagon dual receptor agonist, currently in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The drug has demonstrated compelling weight loss, reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure in clinical trials.

Altimmune continues to progress pemvidutide through clinical trials, with the drug currently being studied in the ongoing IMPACT Phase 2b MASH trial.

Read More